Jayakumar R. Nair

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget et al. · Clinical Cancer Research · 2020 · 221 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer et al. · The Lancet Oncology · 2018 · 212 citations · Full text

Medicine, Gynecology, Oncology +13

Sustained antibody responses depend on CD28 function in bone marrow–resident plasma cells

Ramon Arens, Louise Carlson, Jayakumar R. Nair et al. · The Journal of Experimental Medicine · 2011 · 177 citations · Full text

Life Sciences, Cell Biology, Immunology +16

CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma

Megan Murray, Catherine M. Gavile, Jayakumar R. Nair et al. · Blood · 2014 · 92 citations · Full text

Medicine, Immunology, Oncology +12

CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment

Jayakumar R. Nair, Louise Carlson, Chandana Koorella et al. · The Journal of Immunology · 2011 · 89 citations · Full text

Medicine, Cell Biology, Immunology +17